The Essential Role of Real World Evidence Combating COVID-19
Are you prepared for potential accelerated approval requirements?
ISPE’s Position on Real World Evidence (RWE)
Read more about the February 2020 position on RWE from ISPE.
Lack of Label Alignment & Patient Safety Implications
Read the full article from UBC’s pharmacovigilance team in Drugs Real World Outcomes.
Risk Management Plan Development & Implementation
Listen to the full podcast from UBC with PharmaVOICE here.
Top Trends in Oncology Patient Support
Find out what access and adherence challenges patients will need to overcome in the evolving oncology market.
Are You Ready For Sentinel? | New RWE Safety Initiative
With continued investment in the RWE space, find out how to meet the needs of regulators, payers, and prescribers.
Immunogenicity: Meeting the Safety Reporting Requirements
Discover why it is imperative to assess the potential of therapeutic proteins throughout the product lifecycle.
DIA 2019: Watch the Wrap-up of UBC’s Participation
See more of the developments UBC’s evidence development and safety & risk management teams discussed.
World Cancer Day – Making a Difference in Oncology
February 4th is World Cancer Day, a global event on which we are united to spread awareness, education, and hope for this pervasive disease.
How a Product NDC Change Impacts Your Rare Disease Patients
Find out more on the potential impact a product NDC change may have on your patient population.
